Physician profile
Debralee Pasek
NPI 1356750863
$1,206.06
in general payments reported to CMS, 2019-2025
11 companies · $274 in 2025
The $274 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $263 · 2022: $96.91 · 2023: $278 · 2024: $294 · 2025: $274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $847.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $846.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $187.65 | 2022-2024 | Repatha, Otezla |
| Lilly USA, LLC | $187.35 | 2021-2024 | Mounjaro, Zepbound |
| Novo Nordisk INC | $147.59 | 2021-2023 | Ozempic, Rybelsus |
| Beta Bionics, INC. | $143.92 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Sequel Med Tech, LLC | $129.91 | 2025 | Twiist |
| Axsome Therapeutics, INC. | $109.01 | 2024 | Auvelity |
| Esperion Therapeutics, INC. | $99.78 | 2021 | |
| Amarin Pharma, INC. | $73.16 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.22 | 2023 | Jardiance, Tradjenta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.79 | 2023-2024 | Relistor, Trulance, Xifaxan |
| Sanofi-Aventis U.S. LLC | $30.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debralee Pasek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.